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Unraveling the mechanisms used by the immune system to ﬁght cancer development is one of the most ambitious undertakings in
immunology. Detailed knowledge regarding the mechanisms of induction of tolerance and immunosuppression within the tumor
microenvironment will contribute to the development of highly eﬀective tumor eradication strategies. Research within the last few
decades has shed more light on the matter. This paper aims to give an overview on the current knowledge of the main tolerance
and immunosuppression mechanisms elicited within the tumor microenvironment, with the focus on development of eﬀective
immunotherapeutic strategies to improve homing and activity of immune eﬀector cells to tumors.
1. GeneralIntroduction
In the beginning of the 20th century, the concept according
to which the immune system can be manipulated for tumor
prevention or tumor treatment has emerged. Around half a
century later, Burnet postulated the existence of a complex
immunological mechanism capable of eliminating poten-
tially malignant cells and, thus, gave birth to what would
afterwards be called the cancer immunosurveillance theory
[1]. In later years, strong evidence supporting the existence
of intricate antitumor immune responses lead to the more
exhaustive concept of cancer immunoediting. According to
this concept, the multistep process of cancer development
consists of three phases. The ﬁrst phase, of elimination, is
similar to the cancer immunosurveillance theory. Malignant
cells, generated after genetic modiﬁcations that may occur
during cell division cycles, present the singular property
of expressing tumor antigens, a feature which makes them
immunologically distinguishable from nonmalignant cells.
Recognition of these tumor antigens by cells belonging to
the host immune system leads to development of antitumor
immune responses. Within the second phase, of equilibrium,
a dynamic balance between the tumor microenvironment
and the host immune responses is established. However, due
to the negative activity of the tumor microenvironment as a
dynamic inducer of immune cell anergy or death [2, 3], these
antitumor immune responses are apparently insuﬃcient to
completely eradicate tumors. Hence, the third phase, of
escape, consists of development of immune resistant tumor
variants into fully grown and progressive clinical tumors [4,
5]. Here, the concept of cancer immunotherapy comes into
play. Although the host immune system is clearly capable of
recognizingcancercells[6],theabilitytowhichitcancontrol
tumor growth remains very limited. Diﬀerent explanations
canbeenvisagedtojustifythedecreasedantitumoractivityof
the immune system. All of them take into account two major
obstacles: on one hand, reduced homing of immune cells to
thetumorsiteand,ontheother,hamperingoftheantitumor
immune functions due to tumor microenvironment or
immunomodulatory properties of suppressive cell popula-
tions. Cancer-directed immunotherapies encompass diverse
attemptseithertostimulatetheantitumorimmunesystemor
toinactivateanddepleteprotumorimmunecellpopulations.
Eﬀective antitumor immunotherapeutic strategies take into
account the complex interplay between innate, nonspeciﬁc
and adaptive, antigen-speciﬁc, immune responses.2 Clinical and Developmental Immunology
This paper aims to give an overview on the current
knowledge of the main tolerance and immunosuppression
mechanisms elicited within the tumor microenvironment,
with the focus on development of eﬀective immunothera-
peutic strategies to improve homing and activity of immune
eﬀector cells to tumors.
2. The Balance of Immune Surveillance
in the Tumor: Navigatingbetween
ScyllaandCharybdis
An increasing body of evidence substantiates the concept
that speciﬁc cell populations from both the innate and
adaptive immune systems interact with developing tumors
and frequently contribute to the arrest of tumor growth
and induce tumor regression in animal models and cancer
patients. To counteract the antitumor activity of these
eﬀector cells, regulatory cell populations have emerged,
capable of suppressing the antitumor immune responses
through a large array of mechanisms. These silencing or
suppression mechanisms can be functionally divided in
two main categories: tolerance mechanisms, characterized
by the absence of an immune response only to a speciﬁc
set of antigens and maintenance of normal responses to
all other antigens and immunosuppression mechanisms,
characterized by an impaired ability of the immune system
to ﬁght cancer development.
2.1. Induction of Tolerance Mechanisms. Most often, tol-
erance mechanisms are directed against the antitumor
activity elicited by cell populations belonging to the adap-
tive immune system. The main targets of these tolerance
mechanisms are Th1 CD4+ T cells and cytotoxic CD8+ T
lymphocytes (CTLs). Apart from these adaptive immune
populations, dendritic cells (DCs) are a distinct cell subset
with the capacity to initiate primary and secondary T-
lymphocyte responses against developing cancer, thus rep-
resenting a putative target for tolerance induction. Both the
importance and relevance of these immune populations and
the tolerance mechanisms they are the target of are shortly
addressed below.
2.1.1. Dendritic Cells. Alongside macrophages and B lym-
phocytes, DCs comprise one of the three main professional
APCpopulations.Withinthecontextoftumordevelopment,
their crucial importance stems from the capacity to engulf,
process, and present tumor-associated antigens (TAAs)
and thus generate tumor-speciﬁc immunity. Generation of
potentantitumorimmunitybyDCsistheresultofacomplex
process comprising three major steps: proper presentation
of TAAs to T lymphocytes, activation of T lymphocytes in
a speciﬁc manner as a response to TAAs presentation, and
homing of these speciﬁc T cells to the tumor site, where
they exert cytolytic activity against tumor cells expressing
the TAAs [7]. Tumor escape mechanisms developed during
cancer progression can occur at any of these various levels.
With respect to the ﬁrst step, these escape mechanisms
generally translate into a deﬁcit in antigen presentation.
This deﬁcit stems from two major sources: on one hand, a
decreased number and function of APCs, and on the other, a
semimature phenotype. One of the earlier studies indicating
the eﬀects of defective antigen, presentation by DCs is
performed in a murine model bearing tumors transfected
with a human p53 minigene. Both in vitro restimulation of
T cells isolated from either control or tumor-bearing mice
and in vivo induction of CTLs by DCs from tumor-bearing
mice were signiﬁcantly decreased in comparison with the
same eﬀects exerted by DCs isolated from control mice [8].
Later research in this direction further substantiates these
ﬁndings in various clinical models. A study performed on
DCsisolatedfromrenalcellcarcinomapatientsindicatesthat
lessthan10%ofthetotalDCpopulationrepresentsactivated
cells capable of antigen presentation and T cell stimulation
[9]. The situation proves to be similar in patients with
both advanced breast cancer [10, 11] and non-Hodgkin’s
lymphoma[12].Moreover,DCsexposedtoindoleamine2,3-
dioxygenase [13], transforming growth factor-beta (TGF-β)
or prostaglandins, have been shown to induce tolerance and
anergy leading to failure of recognizing tumor cells.
2.1.2. Th1 CD4+ Tl y m p h o c y t e s . Although not directly capa-
ble of antitumor activity due to their lack of cytotoxic and
phagocytic properties, CD4+ T cells, also known as mature T
helper cells, play a crucial role in the initiation and activation
of the antitumor immune response. In accordance with their
phenotypic characteristics and function, CD4+ T cells can
be divided in two types. Type 1, IL-12 polarized CD4+ T
cells (Th1) provide help to cytotoxic CD8+ T cells, amongst
others by stimulating their proliferation and inducing IFN-
γ secretion once antigen-speciﬁc immunity has developed
[14]. In contrast, type 2, IL-4 polarized [15]C D 4 + Tc e l l s
(Th2) secrete cytokines which induce neutralizing antibody
production by B cells, thus directing immunity towards a
tumor-promoting type 2 response.
2.1.3. Cytotoxic CD8+ Tl y m p h o c y t e s . Cytotoxic T cells con-
stitute a subgroup of T lymphocytes able to induce death of
tumor cells and infected or otherwise dysfunctional somatic
cells, following their activation. The activation process of
cytotoxic CD8+ T lymphocytes relies on various simulta-
neous interactions between molecules which are expressed
on the surface of the CD8+ T cell itself and corresponding
molecules located on the surface of the antigen-presenting
cell (APC). The ﬁrst activation cue of CD8+ T cells consists
of the interaction between their membrane T cell receptor
(TCR) and peptide-bound MHC class I molecules located
on the surface of APCs. Following this cue, a second
signal comprising of interactions between the costimulatory
molecules CD28 (located on the surface of CD8+ T cells)
and CD80 or CD86 (located on the surface of APCs)
can develop. Depending on the case, this second signal
can be substituted by cytotoxic T cell stimulation with
cytokinesreleasedbyhelperTcells.SimilarlytoCD4+ Tcells,
CD8+ T cells can also be divided in diﬀerent subsets [16],
according to their phenotypical and functional properties.
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cells that have not yet encountered their cognate antigen
in the periphery. Upon antigen recognition, they become
memory CD44high CD8+ T cells with a higher sensitivity
to TCR/CD8 signaling in response to subsequent antigen
stimulation [17]. Eﬀector memory CD8+CD44+ Tc e l l s
(Tem), characterized by low expression of markers necessary
for cellular extravasation (e.g., CD62L), have been shown to
restore systemic antitumor immunity in mouse models of
lung and mammary carcinoma [18]. When compared with
Tem cells, central memory T cells (Tcm), phenotypically
deﬁned as CD8+CD44+CD62L+CD127+,c o n f e rs u p e r i o r
immunological protection against viruses, bacteria [19], and
cancer [20]. antitumor eﬀector T cells can be obtained by
systemic delivery of IL-12 and GM-CSF to tumors or by
activation of tumor-resident CD8+ Te ﬀector/memory cells
[21]. By releasing various cytokines, such as perforin and
granzyme B, these eﬀector T cells are capable of inducing
apoptotic death of tumor cells. The activity of these adaptive
immune-cell populations is being continuously targeted by
the tumor microenvironment, through a versatile array of
either tolerance or immunosuppression mechanisms.
2.1.4. Tolerance Mechanisms. When talking about cancer de-
velopment and progression, one should take into account
twomaintypesofalterationswithinthetumorenvironment:
eﬀector-cell related tolerance or immunosuppression and
tumor-cell associated alterations. Intrinsic alterations of the
tumor cells lead to decrease or disappearance of immuno-
genicity, whereas extrinsic alterations are induced by the
tumor cells themselves, however exerting their activity on
eﬀector T cells within the tumor microenvironment. The
latter of the two comprises more varied and versatile escape
mechanisms, as they can either elicit a proximal eﬀect, on
thesurroundingmicroenvironmentoradistanteﬀect,onthe
hostimmunesystemgivingrisetothestateofimmunological
tolerance. A proximal eﬀect of colon cancer cells, which leads
to evasion of FasL mediated cell death, is secretion of decoy
receptors that bind and neutralize FasL [22]. On the other
hand, distant eﬀects exerted on the host immune system
consist of a wide array of tolerance mechanisms. One very
eﬃcacious tolerance mechanism is deletion of eﬀectorT cells
due to expression of death-inducing ligands by cancer cells
[23, 24]. Direct tolerization of antitumor T cells by tumor
cell-induced TGF-β signaling is another highly eﬀective
mechanism, leading to inhibition of master transcriptional
regulators of CD4+ T cells [25] and signiﬁcantly decreased
function and frequency of CTLs (cytotoxic T lymphocytes)
in a thymoma mouse model [26]. The main tolerance
mechanisms leading to decreased numbers of antitumor
eﬀector T cells, coupled with increased numbers of low-
aﬃnityautoreactiveTcells[27],areconstitutedbyignorance
and anergy. Immunological ignorance is characterized by
lack of contact with the antigens able to induce phenotypical
changes, whereas anergy arises after negative regulation
induced by diﬀerent types of host factors (e.g., suppres-
sor cells, their secreted cytokines) [28]. Other competent
tolerance mechanisms are deﬁcient priming of antitumor
eﬀector T cells [29] and increased expression of inhibitors
which block complement mediated lysis of tumor cells [30].
However, regardless of the tolerance mechanism exerted by
tumor cells, the end result consists of reduced or completely
suppressed cytolytic activity of intratumoral eﬀector T cells.
Strategies aimed at increasing the activity of these immune
eﬀectorcellsatthetumorsitewillbeaddressedinSection 3.2
of this paper.
2.2. Induction of Immunosuppression Mechanisms. When
compared to mechanisms of tolerance induction, the
machinery of antitumor Immunosuppression is more ver-
satile, since it encompasses a large variety of tools used
by the tumor environment to target various mechanisms
of inhibition of tumor growth and development. From
a cellular point of view, the most widely encountered
suppressive cell populations within the tumor environment
are macrophages, myeloid derived suppressor cells, and
regulatory T cells. The mechanisms by which these cell
populationsmanagetogiverisetotumor-immuneescapeare
described below.
2.2.1. Tumor Associated Macrophages (TAMs). Tumor-
induced recruitment and expansion of regulatory cell
populations is aimed at both the innate and adaptive
immune systems. Concerning recruitment of suppressive
innate immune populations, one clear example is given by
TAMs. Similarly to CD4+ T cells in adaptive immunity, the
innate immune populations of macrophages can be either
anti- or protumorigenic, depending on their phenotype
[31]. Antitumorigenic inﬁltrating macrophages, “classically
activated” by the action of microenvironmental signals such
as IFN-γ and bacterial factors, are polarized towards the M1
phenotype [32] and elicit cytotoxic activity against tumor
cells in vivo [33], through their production of Th1 cytokines
and iNOS. These macrophages also have the capacity to
function as antigen presenting cells [34] that activate CTLs.
On the other hand, TAMs are “alternatively” activated by
Th2cytokinessuchasIL-4orIL-13[35]towardsanM2non-
cytotoxic phenotype. These M2 macrophages are frequently
found in solid tumors, where they promote remodeling
of the extracellular matrix and secrete growth factors,
therefore, inducing tumor-speciﬁc neoangiogenesis [36].
Also,diﬀerentstudieshaveunderlinedtheircapacitytocause
tumor growth both directly, by production of cytokines that
stimulate proliferation of tumor cells [37], and indirectly
by stimulating proliferation of endothelial cells [38]. For
example, in the HPV16 E6- and E7-expressing TC-1 tumor
mouse model, TAMs were shown to cause suppression of the
antitumor T-cell response [39], while their secreted IL-10
cytokine subsequently induced a regulatory T cell phenotype
[40].
2.2.2. Myeloid-Derived Suppressor Cells (MDSCs). MDSCs
represent a highly heterogenic population of incompletely
maturedgranulocytes,macrophages,anddendriticcells[41],
with diﬀerent morphology, functions, and diﬀerentiation
conditions,whencomparedtoTAMs[42].AlthoughMDSCs4 Clinical and Developmental Immunology
are capable of immune response regulation in healthy indi-
viduals, it has been observed that they dramatically expand
during cancer development and treatment (Draghiciu O,
WalczakM, Nijman HW, and DaemenT, unpublished obser-
vations), inﬂammation conditions or chronic infections [43,
44].Characterizedbyahighphenotypicalvariety,theycanbe
generally identiﬁed in mice as CD11b+Gr1+ cells [45]. After
tumor-induced expansion, they can be divided in two main
subsets, depending primarily on their ancestors, but also on
the suppression mechanisms they exert: monocytic MDSCs,
with a CD11b+LY6G−LY6Chigh phenotype, and granulo-
cytic MDSCs, with a CD11b+LY6G+LY6Clow phenotype. In
humans, MDSCs are characterized as CD11b+CD14−CD33+
cells [46] and have been found to be elevated in patients
with diﬀerent types of cancers [42, 47, 48]. As indicated by
their heterogenic composition, MDSCs can inactivate both
CD4+ and CD8+ T cells [49–52] and therefore display a
large array of mechanisms of T cell function suppression.
One such mechanism is represented by tumor-induced
overexpression of CD80 (B7-1) on the surface of MDSCs, to
which the inhibitory CTLA-4 (CD152) molecule expressed
on CD4+CD25+ T cells binds with high aﬃnity. Binding
of CTLA-4 to CD80 was shown to induce suppression of
antigen-speciﬁc immune responses [53]. High production
of arginase [54, 55] constitutes a common suppressive
mechanism for all subsets of MDSCs. Granulocytic MDSCs
particularly produce high levels of ROS [45], through signal-
ing via the STAT3 pathway, thus leading to direct damage
of the T cell DNA. In contrast, monocytic MDSCs present
increased iNOS activity leading to high NO production [56].
In their turn, increased levels of NO have the capacity to
induce T cell function suppression via diﬀerent inhibition
mechanisms of MHC class II expression [57]o rS T A T 5
signaling cascade [58].
Other mechanisms of MDSC-induced suppression of
eﬀector T cells comprise induction of Tregs by IL-10 secre-
tion in mouse models of colon carcinoma, B16 melanoma,
and in patients with HPV-induced neoplasia [59]; depletion
of cysteine, the essential aminoacid necessary for T cell
activation [60]; secretion of high peroxynitrite levels, which
lead to tumor progression [61]u p r e g u l a t i o no fC o x 2 / P G E 2
[62]. However, the suppressive capacity of MDSCs has
been recently questioned by a highly controversial study
[63] proving that MDSCs from ascites of ovarian cancer
bearingmicewereimmunostimulatory(theyincreasedCTLs
proliferation via CD80 signaling) and adoptive transfer of
these MDSCs induced tumor regression. Lastly, immature
dendritic cells (iDCs) suppress antitumor immunity by
induction of Tregs [64], which in their turn inhibit HPV-
speciﬁc immunity in patients with (pre)malignant cervical
neoplasia [65].
2.2.3. Regulatory T Cells (Tregs). In terms of adaptive im-
munity, one of the most studied immunosuppressive cell
populations is represented by CD4+CD25+FoxP3+ Tregs
[66–68]. Based on their phenotype and localization, Tregs
can be divided into several categories: naturally occurring
FoxP3+ Tregs,generatedinthethymus[69–72],andantigen-
induced Tregs, generated in the periphery [69]. One of the
main deﬁnitory characteristics of CD4+CD25+ Tregs of nor-
mal na¨ ıve mice is represented by the high expression of the
TNF-receptor superfamily member GITR (glucocorticoid-
induced TNFR-related protein) [73]. A more detailed sub-
phenotypic classiﬁcation of Tregs can be found in the review
of Feuerer et al. [74]. Tregs can suppress the antitumor
immune responses through their high surface expression
of CTLA-4, the main T-cell inhibitory signal [75]w h i c h
mediates attenuation of intercellular association. Moreover,
FoxP3+ naturally occurring Tregs (nTregs) are well-known
negative regulatorsof antitumor immunity through diﬀerent
m e d i a t o r s ,s u c ha sF o x P 3[ 76]. Intratumoral accumulation
of FoxP3 leads to poor prognosis of gastric [77] and ovarian
[78] carcinomas. Another mediator of the antitumor eﬀects
of nTregs is IL-2, needed for in vivo/in vitro functional Treg
activation [79] and maintenance of their CD25 expression
[80]. After IL-2 and TGF-β stimulation [81], antigen-
induced FoxP3+ Tregs [82] have also been shown to present
suppressive activity.
Th17 T cells represent a proinﬂammatory subset of
helper T cells, particularly characterized by their capacity to
secreteIL-17exvivoandtoconstitutivelyexpressthelineage-
speciﬁc factor RORyt [83]. Recent studies indicate towards a
close relationship between these Th17 T cells and a distinct
subset of suppressive human memory CD4+FoxP3+ Tregs
[84]. IL23-induced Th17 cells [85] produce IL17, a cytokine
that enhances inﬂammation by stimulating the expression
of other pro-inﬂammatory cytokines and acute phase pro-
teins. Although there are some studies which indicate an
antitumoral function of Th17 cells [86], in vitro experiments
establishing the pro- or antitumor role of these cells are
equivocal. Also, secretion of IL-17 by Th17 T cells promotes
neovascularization and tumor growth in a mouse model of
ovarian cancer and in patients with advanced cancer [87].
Therefore, additional studies are necessary to clarify the
functions of Th17 cells with regards to tumor immunity.
2.3. Other Mechanisms of Tumor Progression. The vast
majority of mechanisms of tumor Immunosuppression are
generated by a complex interplay of activities and factors
belonging to eﬀector-extrinsic suppressor cell populations.
One such eﬀector-extrinsic mechanism that has been shown
to contribute to tumor progression involves the overexpres-
sion of some G-protein-coupled receptors (GPCRs) on the
surface of endothelial cells. In some cases, the eﬀect of this
overexpression was correlated with tumor progression and
metastasis.
In contrast to eﬀector-extrinsic mechanisms of tumor
development, eﬀector-intrinsic mechanisms evolve based on
the upregulation of coinhibitory receptors able to induce
direct lymphocyte inactivation. Both the roles of these
GPCRs and those of upregulated inhibitory factors on
the surface of various immune-cell populations constitute
mechanisms contributing to tumor development.
2.3.1. Endothelin Receptors. Endothelin receptor type A
(ETAR) and type B (ETBR) are GPCRs that belong to
the endothelin system. For a more extensive review, seeClinical and Developmental Immunology 5
Bagnato and Rosan` o[ 88]. Endothelins, the corresponding
ligands of the endothelin receptors, are produced in a
wide variety of cells, ranging from endothelial to smooth-
muscle cells. Synthesis and secretion of endothelin-1 (ET-
1), the corresponding ligand of ETAR, in these cells can be
induced by a large array of stimuli within minutes. ET-1
is not stored in the secretory granules of the endothelial
cells [89]; therefore, its production translates to high ET-
1 plasma levels. Upon binding of its correspondent ligand
ET1 located in the plasma, ETAR promotes vasoconstriction
and tumor cell proliferation through a phospholipase C
dependent mechanism [90]. On the other hand, ETBRw a s
shown to regulate T cell adhesion and tumor homing via NO
and ICAM-1 [91]. Whether these actions are mediated by
ETBR interaction with ET-1 or one of the other endothelin
ligands still remains to be unraveled. In the context of tumor
immunology, expression of ETARh a sb e e nr e p o r t e di n
prostate cancer patients with bone metastasis [92]a n dH P V -
induced neoplasia [93, 94], whereas ETBR expression was
associated with the absence of tumor inﬁltrating lympho-
cytes and decreased survival time of ovarian cancer patients
[91]. Also, upregulation of ETBR in patients with vulvar
squamous cell carcinoma has been correlated with tumor
progression and early metastasis [95].
2.3.2. Negative Regulatory Factors. Programmed death-1
(PD-1), a member of the CD28 superfamily of T cell
regulators [96], is not only a negative regulator of antitumor
immunity, but exhibits a broader expression and function,
since PD-1 knock-out mice have been shown to develop
glomerulonephritis [97] and cardiomyopathy [98]. Expres-
sion of PD-1 can be transiently upregulated on the surface
of activated CD4+ and CD8+ T cells, B and NKT cells
and DCs [99]. Also, high levels of PD-1 have been found
on chronically activated CD8+ T cells and during chronic
infections [100]. PD-1 has two corresponding ligands, PD-
L1 and PD-L2, members of the B7 family [101]. Within
the context of tumor immunology the ligand PD-L1, which
presents an almost ubiquitous expression proﬁle, is most
relevant. Coinhibitory signaling via PD-L1 (but not PD-
L2) is necessary for conversion of na¨ ıve CD4+ Tc e l l st o
adaptive CD4+FoxP3+ Tregs. The PD-1/PD-L1 signaling
pathway is viewed as yet another immune escape mechanism
of solid tumors [102], due to its capacity to inhibit T
cell activation [103] through various downstream signaling
eﬀects. Although not as disputed as the PD-1/PD-L1 system,
the lymphocyte-activation gene (LAG-3), member of the
immunoglobulin superfamily and expressed on the surface
of activated regulatory CD4+ and CD8+ T cells, B cells and
NKT cells have also been shown to contribute to tumor
immunesuppression, as Tregs from LAG-3(−/−) mice present
reduced regulatory activity [104].
2.3.3. Secondary Contributive Mechanisms. Other contribu-
tive mechanisms of tumor development involve blockade of
the granzyme B/perforin pathway by overexpression of the
serine protease inhibitor PI-9/SPI-6 [105], modiﬁcations in
the antigen presentation system [106], developed resistance
of tumor cells to apoptosis, and expression of indoleamine
2,3-dioxygenase (IDO) by the tumor or host stromal cells
[107].
A large array of various tolerance and antitumor Immu-
nosuppression mechanisms contribute to orchestrating
tumor growth and progression. Therefore, eﬀective mono-
or polymodality strategies to improve homing and activity
of immune eﬀector cells to tumors need to be developed
in order for cancer immunotherapy to succeed. A detailed
summary of immunotherapeutic strategies developed so far
and their corresponding eﬃciency will be presented in the
next section of this review.
3.Shifting the Balance: Strategiesto
Improve Homing and Activityof Immune
Effector Cells to Tumors
To counteract the numerous mechanisms of tumor immune
evasion, an ever increasing number of strategies aimed at
improving both innate and adaptive antitumor immunity
has been developed over time. Based on their overall target
aim, these strategies can be categorized as those which
attempt to increase homing of eﬀe c t o rTc e l l st ot u m o r sa n d
those that, directly or indirectly, increase antitumor activity
of intratumoral eﬀector T cells, either by overcoming tumor-
induced tolerance or by overriding the immune-suppression
mechanisms imposed during tumor development.
3.1. Increased Homing. Due to the large variety of escape
mechanisms developed by the tumor microenvironment and
the tumor itself, proper traﬃcking of eﬀector T cells into
the tumor may not always occur. An impaired traﬃcking
of these eﬀector cells to the tumor site will give rise to a
negative regulatory process, leading to tumor development
and progression. Thus, strategies to block this process and
enhance homing of eﬀector cells to tumors are of crucial
importance for ﬁghting tumor progression. The most widely
used strategies to increase recruitment of eﬀector T cells to
tumors aim at targeting both the intrinsic alterations of the
tumor cells and the extrinsic alterations induced at the level
of eﬀector cell populations. These encompass local tumor
irradiation, blockade of endothelin receptors, and eﬀector
CTL antibody-targeting and taxane-based chemotherapy.
3.1.1. Local Tumor Irradiation. Within the clinical setting,
local or total body irradiation is frequently used as adjuvant
therapy, in association with other therapies such as surgery,
hormonal therapy [108], or bone-marrow transplantation.
Evidence is accumulating that local tumor irradiation is
able to modulate expression of receptors and cytokines
by cancer and stroma cells, resulting in tumor microen-
vironment changes that can be used for increasing the
eﬀects of immune therapy [109, 110]. These changes seem
to facilitate recruitment of eﬀector T cells to tumors via
two distinct mechanisms: ﬁrst, by promoting vasculature
normalization [111] and second, by stimulating overexpres-
sion of endothelial adhesion molecules, such as VCAM-1
[112]. More recent studies indicate that irradiation induces6 Clinical and Developmental Immunology
chemokines involved in recruitment of eﬀector T cells, thus
converting tumors into “inﬂamed tissue”, susceptible to the
eﬀector phase of the antitumor immune response [113]. For
example,arecentstudyperformedbyQuezadaetal.inwhich
polyclonal CD4+ and CD8+ T cells, harvested from mice
previously treated with anti-CTLA-4 and depleted of Tregs,
were adoptively transferred into irradiated mice bearing
large tumors indicated increased protection against tumor
outgrowth [114] .T h er e s u l ts e e m e dt ob ea tl e a s tp a r t l y
due to irradiation-induced overexpression of ICAM and
VCAM by the tumor vasculature and increased inﬁltration
of eﬀector T cells to the tumor site. In our hands, local
irradiation of TC-1 (HPV transformed) tumor bearing mice
with diﬀerent irradiation dosages induces increased natural
inﬁltration of both CD8+ eﬀector T cells and CD8+ speciﬁc
CTLs. Also, combination of local TC-1 tumor irradiation
with adoptive transfer of in vitro restimulated CFSE-labeled
speciﬁc CTLs lead to a signiﬁcantly increased homing of the
speciﬁc CTLs to the tumor site (Draghiciu O, Walczak M,
Nijman HW and Daemen T, unpublished data).
3.1.2.EndothelinReceptorsBlockade. Variousstudiesdemon-
strate that endothelial cells from a variety of human cancers
overexpress the endothelin receptors. Hence, blockade of
these receptors seems to be a promising strategy for delaying
tumor development or stopping tumor-cell proliferation.
In fact, selective ETAR blockade by the experimental drug
atrasentan has been shown to delay progression of hormone-
refractory prostate adenocarcinoma [115] and enhance the
eﬀect of paclitaxel/docetaxel used for treatment of prostate
cancer [116] in patients. In a mouse model of HPV-induced
cervical carcinoma, blockade of ETAR caused inhibition of
tumor growth [94]. Although it can be hypothesized that
the eﬀect of ETAR blockade on tumor growth is mediated
by an increase in T cell homing to the tumor site, further
studies need to be performed to elucidate the underlying
mechanisms. On the other hand, in the context of ovarian
and also other cancers, overexpression of ETBR was asso-
ciated with the absence of tumor-inﬁltrating lymphocytes
and short patient survival time [117]. Moreover, it was
shown that interaction between ETBR and its corresponding
ligand ET-1 induces downregulation of ICAM expression,
an eﬀect rescued by administration of the small molecule
inhibitor BQ-788. Neutralization of ETBR by administration
of the inhibitory peptide BQ-788 suppressed intercellular
communication and cell growth in melanoma nude mice
[118] and signiﬁcantly increased T cell homing to tumors in
vivo [117].
3.1.3. Antibody-Mediated Targeting of Eﬀector CTLs. Mono-
clonal antibody therapy is a method most commonly used
to functionally inactivate or deplete suppressive immune
populations such as MDSCs or Tregs (see Section 3.2.1).
However, various studies using bispeciﬁc monoclonal anti-
bodies suggest that this approach is a useful tool with a
larger therapeutic applicancy. Eﬀector CTL targeting aims
at overcoming extrinsic tumor-induced tolerance by making
use of bispeciﬁc monoclonal antibodies. These particular
antibodies are directed against antigens expressed by both
activated T cells and tumor cells and display potent in vitro
[119]a n din vivo [120]e ﬀects against tumor cells. In a
severe combined immunodeﬁciency deﬁcient (SCID) mouse
model, this potent antitumor activity has been enhanced
even further, due to inhibition of apoptosis of antibody-
targeted cytotoxic T cells by costimulation with an anti-
CD28 monoclonal antibody [121].
3.1.4. Taxane-Based Chemotherapy. Another relevant tool to
increase homing of eﬀector T cells to tumors is chemother-
apy with mitotic inhibitors, such as taxanes. Originally,
taxanes have been reported to induce mitotic inhibition
through disruption of microtubule functionality. Other
studies demonstrate their capacity to bind to and block the
function of antiapoptotic molecules expressed on the surface
of tumor cells, like Bcl-2 [122], thus inducing programmed
tumor cell death. A recent study performed by Dirkx and
colleagues aimed at investigating whether inhibition of
angiogenesis could contribute to overcoming tumor escape
from immunity. The results of this study clearly indicated
that the angiogenesis inhibitor paclitaxel was capable of
increasingleukocyterollingonthetumorwallvesselandthus
inﬁltration of circulating eﬀector T cells to the tumor [123].
3.2. Increased Activity. Targeting homing of immune eﬀector
cells to the tumor site may not solve the problem of
eradicating tumor development, as cells that do eﬀectively
home to tumor metastases are often found to be dysfunc-
tional. These ﬁndings point towards existence of various
immunosuppressive mechanisms acquired by the tumor
microenvironment in order to ﬁght immune-induced cancer
regression. T cell anergy due to extrinsic suppression by
regulatory cell populations, inhibition by ligands such as
PDL-1, the action of inhibitory factors such as TGF-β,a n d
metabolic dysregulations by enzymes such as indoleamine-
2,3-dioxygenase (IDO) have all been implicated in generat-
ing this suppressive microenvironment. Eﬀective strategies
aimed at increasing activity of T cells that migrate to
the tumor site address both inhibition of tolerance and
restriction of immunosuppression induced by the tumor
microenvironment. For targeting the inhibition of the above
described negative regulatory mechanisms, several strategies
have been employed over time. Some of the strategies most
widely and successfully used in both tumor mouse models
and cancer patients will be addressed.
3.2.1. Suppressive Immune Populations: Depletion or Func-
tional Inhibition? One commonly used mechanism of tar-
geting innate as well as adaptive immunity for increasing
antitumor activity of eﬀector T cells is depletion of sup-
pressive immune populations. A less intrusive alternative to
immune depletion, widely applied as it has been shown to
lead to tumor regression [124], consists of manipulating the
immune suppressive functions of MDSCs or Tregs. However,
functional inhibition of immune suppressive cells, especially
directed towards complex and versatile cell populations such
as MDSCs, may not be the most suited approach as it is veryClinical and Developmental Immunology 7
likely to lead to development of new inhibitory properties
causing de novo immunosuppression of the previously
restored antitumor immune response.
Diﬀerent depletion methods, with speciﬁcity for the
targeted immune population at hand, have been devel-
oped over time. Regarding TAMs, selective depletion is
promoted by IL-15/TGF-α in human primary colorectal
adenocarcinomas [125]. Although TAMs depletion can be
achieved by diﬀerent approaches, such as blockade of TAMs
chemoattractant chemokines (e.g., blockade of the chemoat-
tractant CCL-2 with the inhibitor molecule bindarit [126]
or vaccination with a legumain-based minigene vaccine
[127]), the most eﬃcient depletion method involves the
usage of clodronate-liposomes. Clodronate-liposomes are
artiﬁcial spheres formed by dispersion of phospholipid
molecules into an aqueous solution of clodronate bispho-
sphonate. Intraperitoneal or subcutaneous administration
of clodronate liposomes induced eﬃcient depletion (75%–
92%) of TAMs in both murine teratocarcinoma and human
rhabdomyosarcoma mouse tumor models [128] and in a
mouse model of human cervical carcinogenesis, respectively
[129]. On the other hand, depletion of MDSCs was achieved
either by treatment with tyrosine kinase inhibitors, such as
sunitinib [130, 131], which also induced reversal of Treg
elevation or by treatment with inhibitors of DNA repli-
cation, such as 5-ﬂuorouracil [132] or gemcitabine [133].
Also, nTreg depletion was obtained in animal models by
administration of anti-CD25 monoclonal antibodies before
inoculation of tumor cells [134]. In line with this approach,
it was recently reported that selective depletion of FoxP3+
Tregs by using transgenic DEREG (depletion of regulatory
T cells) mice, in combination with therapeutic vaccination
against melanoma, greatly enhanced the antitumor eﬀect
[135]. However, other studies in this direction indicate that
this combinatorial approach consisting of Tregs depletion
and vaccination cannot be generalized for obtaining potent
antitumor eﬀects. Depletion of Tregs by treatment with the
novel antifolate receptor 4 antibody did not enhance the
immune response induced by SFVeE6,7 immunization in a
mouse model of cervical carcinoma [136].
Functional inhibition of immunesuppressive proper-
ties of negative regulatory cell populations is yet another
approach towards improving antitumor immunity. One very
good example in this direction is constituted by functional
Treg inhibition. Blockade of the main inhibitory eﬀector
T cell signal CTLA-4, highly expressed on the surface of
Tregs, by using anti-CTLA-4 monoclonal antibodies, has
been shown to neutralize Tregs mediated suppression of
eﬀector T cells [137]. In a similar manner, GITR block-
ade with mono- or polyclonal antibodies also neutralized
nTregs mediated suppression in vitro [138]. Although these
suppressive strategies have been proven eﬃcient, positive
approaches have also been successfully employed: stimula-
tion of human nTregs through TLR8 has been shown to
reverse the inhibitory functions of these cells, via signaling
through the TLR8-MyD88-IRAK4 pathway, thus increasing
antitumor immunity [139]. However, taking into account
the phenotypical and immunesuppressive heterogeneity of
MDSCs, functional inhibition of these cells seems to be
a more challenging matter. Initially, the suppressive activity
of MDSCs has been correlated with the metabolism of
L-arginine, the substrate of both iNOS and arginase-1.
Accordingly, administration of cyclooxygenase 2 inhibitors
has been shown to block production of prostaglandin E2 and
thus induce a signaling cascade leading to downregulation of
both arginase-1 and iNOS expression on MDSCs. In its turn,
this downregulation was associated with increased eﬃcacy of
antitumor immunotherapy [140, 141]. However, nowadays
an increasing body of evidence points towards ROS and
peroxynitrite production as one of the main mechanisms of
MDSC-induced eﬀector T cell inhibition. ROS induces eﬀec-
tor T cell anergy by direct damage at the DNA level, whereas
peroxynitrite is hypothesised to directly nitrosylate intracel-
lular T cell tyrosine to nitrotyrosine, thereby inducing CD8+
T cell unresponsiveness [142]. Inhibition of ROS production
has been shown to abrogate the MDSCs suppressive eﬀects
in vitro [45]. Also, in vitro treatment of isolated MDSCs
with the anti-inﬂammatory triterpenoid drug CDDO-Me
reduced both ROS and peroxynitrite levels, whereas in vivo
administration of CDDO-Me to tumor bearing mice lead to
asigniﬁcantdecreaseintumorsize[124].Thereducedtumor
size after CDDO-Me treatment could partly be explained by
decreased ROS and peroxynitrite production.
Other eﬀective methods of MDSCs manipulation to-
wards a better outcome of the antitumor immune response
include induction of MDSCs diﬀerentiation into myeloid
DCs that have lost their suppressive activity, by administra-
tion of all-trans retinoic acid [143] and inhibition of MDSCs
maturation from precursors, by usage of selective inhibitors
of the STAT3 maturation pathway [144].
3.2.2. Blockade of Negative Regulatory Factors. Within the
context of tumor development and progression, overexpres-
sion of negative regulatory factors, such as PD-1 and LAG-3,
hasoftenbeencorrelatedwithchronicallyactivatedandnon-
functional CD8+ T cells. Hence, blockade of either of these
two factors could be an eﬃcient strategy to induce tumor
regression. In this context, PD-1 blockade has been shown
to increase the induction of eﬀector T cells in the spleen,
prolong T-cell proliferation, and enhance recruitment of
eﬀectorTcellstotumorsites[145].Inmultimodalitytherapy
regimens, PD-1 blockade increased therapeutic eﬃcacy of
total body irradiation and DCs transfer therapy [146]. Also,
antibody blockade of LAG-3 in two murine models of
self- and tumor-tolerance increased the accumulation and
eﬀector function of antigen-speciﬁc CD8+ T cells [147].
Thus, combination of mAb therapy against PD-1 or LAG-
3 with vaccination strategies has been recently demonstrated
to restore the functions of tolerized antigen-speciﬁc CD8+ T
cells [148].
3.2.3. Blockade of TGF-β Induced Signaling. Several ap-
proaches have been employed to induce high avidity eﬀector
T cells in an attempt to target the inhibition of tumor-
induced tolerance. One such approach involves block-
ade of TGF-β induced signaling. In a xenograft mouse8 Clinical and Developmental Immunology
model of prostate cancer, transfer of tumor-reactive TGF-
β-insensitive CD8+ T cells leads to a 50% decrease in
average tumor weight, when compared with tumors of
mice which underwent transfer of na¨ ıve CD8+ Tc e l l s
[149]. Another approach aimed at manipulating TGF-β to
improve antitumor immune responses involves generation
of TGF-β insensitive DC vaccines. Transduced DCs, which
have been rendered insensitive to TGF-β, maintain their
normalphenotype,presentupregulatedexpressionofsurface
costimulatory molecules (CD80/CD86) and induce potent
tumor-speciﬁc cytotoxic T lymphocyte responses in vivo
[150].
3.2.4. Blockade of Indoleamine 2,3-Dioxygenase (IDO). IDO
is an enzyme constitutively expressed by both various tumor
cell lines and diverse human tumors, such as cervical, pan-
creatic, and colorectal carcinomas. IDO-expressing tumors
were shown to block antigen-speciﬁc T cell proliferation,
thus mediating the process of tumor immune escape [151].
Plasmacytoid dendritic cells (pDCs) resident in tumor-
draining lymph nodes were also shown to express high levels
of functionally active IDO, which mediated suppression of
reactive T lymphocytes. Since IDO catalyzes the ﬁrst step
in the metabolism of tryptophan, IDO activity in tumors
and pDCs altogether can be inhibited by various tryptophan
analogues such as 1 methyl-tryptophan. Inhibition of IDO
activity in pDCs by administration of 1 methyl-tryptophan
leads to reversal of T cell suppression [152].
3.2.5. CTLs Manipulation Strategies. So far, proper targeting
and usage of diﬀerent methods to increase host antitumor
immune responses have been discussed. However, one other
option to consider when aiming for tumor eradication
consists of developing strategies which target the expansion
and activation of the eﬀector cell populations themselves.
Withinthiscontext,adoptivecelltherapyorotherdirectCTL
manipulation strategies (such as cisplatin treatment) might
just do the job.
(a) Adoptive Cell Therapy (ACT). Adoptive T cell therapy
is a very widely used clinical method employed for cancer
treatment. More extensive reviews regarding ACT have been
written over time [153–155]; here, some aspects of ACT
relevant to the induction of tumor regression will be brieﬂy
highlighted. T-cell-based ACT constitutes another approach
of increasing eﬀector T-cell number and activity, by in vitro
expansion of a patient’s own CTLs and in vivo reinfusion
of the expanded CTLs into the patient himself, associated
or not with concomitant exogenous administration of IL-2.
ACT can be viewed as a method of indirectly manipulating
the immune system towards the induction of a new CTL
population. In many cases, lymphodepletion is required
before CTL reinfusion, in order to eliminate Tregs or other
competing own lymphocytes. Several studies have already
been performed in this direction and the highest eﬃciency of
ACT has been reached in patients with metastatic melanoma
[156]. In the clinical setting, ACT has been used either as
mono- (e.g., expansion and conversion of Tregs [157]) or in
polymodality treatments, in combination with gene therapy
[158] or total body irradiation to achieve lymphodepletion
[159–161].
(b) Platinum-Based Chemotherapy. Originally, it was shown
thatplatinum-based chemotherapyleadstotumorcellapop-
tosis by binding to and causing DNA crosslinking. Recent
studies aiming to completely unravel the eﬀects of platinum-
based chemotherapy on CD8+ T cell mediated immunity
reported that cisplatin greatly enhances E7-speciﬁc CD8+
T cell immunity induced by DNA vaccination in TC-1
tumor bearing mice [162]. Also, combined chemotherapy
treatments with the two platinum-based drugs paclitaxel
and carboplatin resulted in improved survival in advanced
ovarian cancer patients [163]. The observed improved sur-
vival might be explained by a synergistic eﬀect of combined
therapy, leading to induction of higher cytotoxic T lympho-
cytes frequencies. However, platinum-based drugs do not
constitute the only chemotherapeutics capable of enhancing
the antitumor immune function of eﬀector T cells. The
alkylating drug cyclophosphamide (CTX) is yet another
agent widely used in the chemoimmunotherapy of tumors.
CTX has been shown to synergize with exosome-based
vaccines by abolishing the Tregs suppressive function and
enhancing the vaccine-induced CTL responses in murine
tumormodels[164].Also,CTXtreatmenthasbeenshownto
induce diﬀerentiation of CD4+ Th17 cells in cancer patients
[165].
3.2.6. Therapeutic Vaccination. Although the mechanisms by
which chronic viruses or bacteria infections promote cancer
are quite diverse, a common feature is given by the fact that
development of cancer takes place in the setting of chronic
infections [166]. To this end, prophylactic immunization
strategieshavebeendevelopedtoreducecancerburdenanda
very suitable example is given by production of the two pro-
phylactic vaccines Gardasil and Cervarix for HPV-induced
cervicalcancer.Regardingtherapeuticvaccination,Provenge,
containingtheactivesubstancesipuleucel-T,istheﬁrstthera-
peutic cancer vaccine that demonstrated eﬀectivenessby pro-
longing life of patients with metastatic prostate cancer [167].
Sipuleucel-Tisconstitutedbyperipheralbloodmononuclear
cells activated ex vivo by the recombinant human PAP-GM-
CSF fusion protein (prostatic acid phosphatase-granulocyte-
macrophage colony-stimulating factor [168]).
Another therapeutic vaccine, which induced both strong,
long-lasting CTL responses in a mouse model of cervical
carcinoma and eﬀective eradication of established tumors
of HPV-transformed cells [169, 170], is the recombinant
Semliki Forest virus vaccine (rSFV). Constituted of a fusion
protein of HPV16 E6 and E7 (SFVeE6,7), this vaccine
was able to induce speciﬁc CTL activity in immune-
tolerant, E6/E7 transgenic mice [171]. A comparative study
between the prime-boosting eﬃcacy of SFVeE6,7 and that
of the recombinant adenovirus type 5 vector expressing the
same antigen construct (Ad-eE6,7) revealed that SFVeE6,7
vaccination lead to higher precursor CTL frequencies andClinical and Developmental Immunology 9
activity when compared to Ad-eE6,7 vaccination. The eﬃ-
cacy of SFVeE6,7 vaccination in murine tumor treatment
experiments was signiﬁcantly higher than that of the Ad-
eE6,7 counterpart [172]. Also, low doses of IL-12 expressed
by a SFV virus vector (SFV-IL12) augmented the antigen-
speciﬁc and antitumor responses induced by the virus vector
alone [173]. More recent studies showed that the rSFV
vaccine induces strong CTL responses in both homologous
[174] and heterologous [175] prime-boost immunization
regimens in a mouse model of cervical cancer. However,
contrary to the excellent therapeutic antitumor responses
observed in animal tumors, the clinical results in patients
are modest. Explanations for this outcome may be either
insuﬃcient activation of antigen-speciﬁc immune eﬀector
cells or development of immune-suppression mechanisms.
For this purpose, development of new multimodality strate-
gies in which vaccination therapies are combined with
eﬀective antitumor approaches aimed at increasing homing
and activity of immune eﬀector cells to tumors is of crucial
importance and thus, an important step forward in cancer
immunotherapy.
4. Concluding Remarks
In the last few decades, major progress has been achieved
within the ﬁeld of cancer immunotherapy. However, despite
this progress, the outcomes of clinical trials performed so
far are signiﬁcantly lower than expected. Contrary to the
excellent therapeutic antitumor responses observed in ani-
maltumors,theclinicalresultsinpatientsaremodest.Expla-
nations for this outcome may be either insuﬃcient homing
and activation of antigen-speciﬁc immune eﬀector cells
within the tumor or development of immune-suppressive
mechanisms, capable of inhibiting their cytolytic activity.
Both recent experimental studies and emerging clinical trials
indicatetowardsdevelopmentofgoodvaccinationstrategies,
leading to generation of high levels of eﬀector T cells with
a proper phenotype and speciﬁcity, as a possible answer to
theproblem.Adesirable,highlyeﬀectivevaccinationstrategy
should accomplish two purposes. On one hand, it should
aim at increasing both the recruitment of antigen-speciﬁc
eﬀectorTcellstothetumorsiteandtheirintratumoralarrest
for the time necessary to exert their antitumor activity. For
this purpose, combination of vaccination regimens, leading
to induction of high levels of antigen-speciﬁc eﬀector T cells,
with ways to enhance homing of these cells to the tumor
site, such as local tumor irradiation, endothelin B receptor
blockade, antibody-mediated targeting of eﬀector CTLs, or
taxane-based chemotherapy, could be a promising strategy.
On the other hand, targeting only the homing of vaccine-
induced eﬀector T cells to the tumor site might not be
enough. We may speculate that once these cells have reached
the tumor, they can be anergized or tolerized by diverse
immune-suppressive mechanisms developed by the tumor
itself or by secondary immune-suppressive populations. To
counteract this eﬀect, strategies which aim at maintaining
or potentiating the activity of these intratumoral antigen-
speciﬁc eﬀector T cells, such as depletion or functional
inhibition of immune-suppressive populations, blockade of
negative regulatory factors, CTLs manipulation methods, or
therapeutic vaccination are stringently necessary.
Concluding, development of new multimodality strate-
gies in which vaccination therapies are combined with
eﬀective antitumor approaches aimed at increasing homing
of immune eﬀector cells to tumors and their intratumoral
activity is of crucialimportance andmight representthe next
step forward in cancer immunotherapy.
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